Drugs / cAd3-EBO S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04041570 | Jul 2019 → Sep 2020 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04723602 Comparator | Jan → Dec 2021 | Ebola hemorrhagic fever, Marburg hemorrhagic fever | Albert B. Sabin Vaccine Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cAd3-EBO-S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04723602 ↗ |
| Modality | Vaccine | “a chimpanzee adenovirus serotype 3 vector-based Ebola vaccine” NCT04041570 ↗ |
| Route | Intramuscular | “is administered intramuscularly (IM)” NCT04041570 ↗ |